Drug Profile
Research programme: arthritis therapeutics - Oscotec
Latest Information Update: 30 Aug 2023
Price :
$50
*
At a glance
- Originator Oscotec
- Class Antirheumatics
- Mechanism of Action ADAM protein inhibitors; TYRO3 receptor protein tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Arthritis
Most Recent Events
- 30 Aug 2023 Discontinued - Preclinical for Arthritis in South Korea (PO) (Oscotec pipeline, August 2023)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Arthritis in South Korea (PO)
- 19 Feb 2016 Preclinical trials in Arthritis in South Korea (PO)